Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Cabozantinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.